Neuropsychiatric symptoms related to interferon alpha;Objawy neuropsychiatryczne w trakcie leczenia interferonem alfa

Psychiatria Polska

Volumn 40, Issue 4, 2006, Pages 787-797

  Małyszczak, Krzysztof ^a   Inglot, Małgorzata ^a   Pawłowski, Tomasz ^a   Czarnecki, Marcin ^a   Rymer, Weronika ^a   Kiejna, Andrzej ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Depression; Interferon

Indexed keywords

2,3 INDOLAMINEDIOXYGENASE; ALPHA INTERFERON; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; ENZYME; KYNURENINE; NALTREXONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OPIATE RECEPTOR; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ANXIETY DISORDER; ARTICLE; CHRONIC FATIGUE SYNDROME; COGNITIVE DEFECT; DEPRESSION; DYSPHORIA; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS C; HUMAN; ILLNESS BEHAVIOR; KAPOSI SARCOMA; KIDNEY CANCER; MANIA; MELANOMA; NEUROPSYCHIATRY; NEUROTRANSMISSION; PSYCHOEDUCATION; PSYCHOPATHY; PSYCHOSIS; PSYCHOTHERAPY;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BRAIN; HUMANS; INTERFERON-ALPHA; MENTAL DISORDERS; RECEPTORS, SEROTONIN;

EID: 33748484248     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology; 1996 26 (3 supl. 1): 112-121.
2. Debien C. De Chouly De Lenclave MB, Foutrein P, Bailly D. Alpha-interferon and mental disorders. Encephale. 2001; 27: 308-317.
3. Kamei S, Sakai T, Matsuura M, Tanaka N, Kojima T, Arakawa Y, Matsukawa Y, Mizutani T, Oga K, Ohkubo H, Matsumura H, Hirayanagi K. Alterations of quantitative EEG and mini-mental state examination in interferon-alpha-treated hepatitis C. Eur. Neurol. 2002; 48: 102-107.
4. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse event in 11 242 patients with chronic hepatitis treated with alfa interferon. J. Hepatol. 1996; 24: 38-47.
5. Maddock C, Baita A, Orru MG, Sitzia R, Costa A, Muntoni E, Farci MG, Carpiniello B, Pariante CM. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J. Psychopharmacol. 2004; 18: 41-46.
6. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005; 19: 105-123.
7. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J. Clin. Psychiatry 2005; 66: 41-48.
8. Laguno M, Blanch J, Murillas J, Blanco JL, Leon A, Lonca M, Larrousse M, Biglia A, Martinez E, Garcia F, Miro JM, de Pablo J, Gatell JM, Mallolas J. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C. Antivir Ther. 2004; 9: 905-909.
9. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J. Clin. Psychiatry 2003; 64: 708-714.
10. Kraus MR, Schafer A, Csef H, Scheurlen M, Psychiatric side effects of pegylated interferon alfa-2b sa compared to conventional interferon alfa-2b in patients with chonic hepatitis C. World J. Gastroenterol. 2005; 11: 1769-1774.
11. Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willebring ML. Suicidal Ideation during interferon-alpha-2b and ribavirin treatment of patients with chronic hepatitis C. Gen. Hosp. Psychiatry 2004; 237-240.
12. Dieprink E, Willenbring M, Ho SB. Neuropsychiatric Symptoms Associated with Hepatitis C and Interferon Alpha: A Review. Am. J. Psychiatry 2000; 157: 867-876.
13. Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin. Neurosc. 2000; 54: 565-572.
14. Hosoda S, Kohno M, Kumada H. Psychiatric symptoms related to interferon treatment for chronic hepatitis. Seishin Shinkeigaku Zasshi. 2003; 105: 768-786.
15. Beratis S, Katrivanou A, Georgiou S, Monastirli A, Pasmatzi E, Gourzis P, Tsambaos D. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment. J. Psychosom. Res. 2005; 58: 15-18.
16. Otsubo T, Miyaoka H, Kamijima K, Onuki M, Ishii M, Mitamura K. Depression during interferon therapy in chronic hepatitis C patients - a prospective study. Seishin Shinkeigaku Zasshi. 1997; 99: 101-127.
17. McHutchison JG, Gordon SC, Shiff ER, Schiffman ML, Lee W, Rustgi V, Goodman Z, Ling MH, Cort S, Albrecht J. Interferon alfa-2b alone or in combination with ribawiryn as initial treatment for chronic hepatitis C. N. Engl. J. Med. 1998; 339: 1485-1492.
18. Rifflet H, Vuillemin E, Oberti F, Duverger P, Laine P, Garre JB, Cales P. Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha. Gastroenterol. Clin. Biol. 1998; 22: 353-357.
19. Koseki K, Nakano M, Takaiwa M, Kamata T, Yoshida J. Suicidal attempts In three postoperative patients with renal cancer after alpha interferon withdrawal. Nippon Hinyokika Gakkai Zasshi. 2000; 91: 29-32.
20. Smith A, Tyrell D, Coyle K, Higgins P. Effects of interferon alpha on performance in men: a preliminary report. Psychopharmacology 1988; 96: 414-416.
21. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxeline responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26: 643-652.
22. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, Miller AH. Interferon-alpha-induced changes in tryptofan metabolism. Relationship to depression and paroxetine treatment. Biol. Psychiatry 2003; 54: 906-914.
23. Poutianinen E, Hokkanen L, Niemi ML, Farkkila M. Reversible cognitive decline during high-dose alpha-interferon treatment. Pharmacol. Biochem. Behav. 1994; 47: 901-905.
24. Merimsky O, Reider-Groswasser I, Inbar M, Chaitchik S. Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma. Eur. J. Cancer. 1990; 26: 596-600.
25. Amodio P, De Toni EN, Cavaletto L, Mapelli D, Bernardinello E, Del Piccolo F, Bergamelli C, Constanzo R, Bergamaschi F, Poma SZ, Chemello L, Gatta A, Perini G. J. Mood, cognition and EEG changes during interferon alfa (alfa-IFN) treatment for chronic hepatitis C. Afect Disord. 2005; 84: 93-98.
26. Caraceni A, Gangeri L, Martini C, Belli F, Brunelli C, Baldini M, Mascheroni L, Lenisa L, Cascinelli N. Neurotoxicity of interferon-a in melanoma therapy. Cancer. 1998; 83: 482-489.
27. Nesic Z, Delic D, Prostran M, Stojanovic R, Vuckovic S, Todorovic Z. Psychiatric adverse effects induced by recombinant interferon alfa in patients with chronic hepatitis C. Med. Pregl. 2004; 57: 219-226.
28. Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. Cancer. 2001; 15, 92 (Supl.): 1664-1668.
29. Parnet P, Kelley KW, Bluthe RM, Dantzer R. Expression and regulation of interleukin receptors in the brain. Role in cytokines-induced sickness behavior. J. Neuroimmunol. 2002; 125: 5-14.
30. Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur. J. Pharmacol. 2004; 500: 399-411.
31. Calvert MC, Gresser I. Interferon enhances the excitability of cultured neurons. Nature. 1979; 178: 558-560.
32. Rothwell NJ, Hopkins SJ. Cytokines and the nervous system, IL: actions and mechanisms of action. Trends Neurosc. 1995; 18: 130-136.
33. Wichers M, Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int. J. Neuropsychopharmacol. 2002; 5: 375-388.
34. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005; 201-217.
35. Stahl SM. Mixed Anxiety and Depression: Clinical Implications, Journal of Clinical Psychiatry 1993; 54, 1: 33-38.
36. Małyszczak K, Wróbel T, Mazur G, Lindner K, Pyszel A, Kiejna A, Kuliczkowski K, Andrzejak A. Objawy lȩkowe i depresyjne u pacjentów leczonych na nowotwory hematologiczne. Psychiatr. Pol. 2005; 34: 33-40.
37. Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 1998; 62: 583-606.
38. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer H, Macs M. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J. Clin. Psychopharmacol. 2002; 22: 86-90.
39. Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the patophysiology of interferon-α-induced depression. J. Psychiatry Neurosci. 2004; 29: 11-17.
40. Ho B, Huo YY, Lu JG, Tansey LW, Levin VA. Opioid-dopaminergic mechanisms in the potentiation of d-amphetamine discrimination by interferon-alpha. Pharmacol. Bopchem. Behav. 1992; 42: 57-00.
41. Shaefer M, Schwaiger M, Pich M, Lieb K, Heinz A. Neurotransmitter Changes by Interferon-Alfa and Therapeutic Implications. Pharmacopsychiatry 2003; 36, suppl 3: 203-206.
42. Sammut S, Bethus I, Goodall G, Muscat R. Antidepressant reversal of interferon-alpha-induced anhedonia. Physiol. Behav. 2002; 15, 75: 765-772.
43. Dubas-Slemp H, Marmurowska-Michałowska H, Szuster-Ciesielska A, Kamińska T, Kandefer-Szerszeń M. Rola cytokin w depresji. Psychiatr. Pol. 2003; 37: 787-798.
44. Valentine AD, Meyers CA, Kling MA, Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol. 1998; 25: 39-47.